Sign In
Buy MESO
$16.22
+0.780 (+5.05%)
At Close: Jul 13, 2026
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis
07:59am, Saturday, 11'th Jul 2026
Mesoblast transitions to a commercial-stage company, anchored by FDA-approved Ryoncil and robust early revenue growth. Ryoncil's regulatory, reimbursement, and manufacturing precedents de-risk MESO's
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
08:30pm, Thursday, 09'th Jul 2026
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a B
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
08:59pm, Wednesday, 24'th Jun 2026
Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
08:55pm, Wednesday, 29'th Apr 2026
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesob
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
08:55pm, Wednesday, 29'th Apr 2026
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesob
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
08:53pm, Tuesday, 28'th Apr 2026
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
08:10pm, Tuesday, 14'th Apr 2026
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an
First Look: JPM beats, RVMD surges, NXST-TGNA paused
07:37am, Tuesday, 14'th Apr 2026
Stock News JPMorgan tops Q1 estimates: JPMorgan Chase (JPM) posted Q1 EPS of $5.94 on revenue of $50.54B, beating estimates on stronger fixed income trading and
Gregory George Acquires 1,981,890 Shares of Mesoblast (NASDAQ:MESO) Stock
04:19am, Sunday, 12'th Apr 2026
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George bought 1,981,890 shares of Mesoblast stock in a transaction that occurred on Thursday, April 9th. The stock was purchased at
Gregory George Purchases 4,000,000 Shares of Mesoblast (NASDAQ:MESO) Stock
04:19am, Sunday, 12'th Apr 2026
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George acquired 4,000,000 shares of the business's stock in a transaction on Saturday, April 4th. The stock was acquired at an avera
Gregory George Buys 2,324,072 Shares of Mesoblast (NASDAQ:MESO) Stock
04:19am, Sunday, 12'th Apr 2026
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George acquired 2,324,072 shares of the stock in a transaction dated Friday, April 10th. The shares were purchased at an average pri
Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts
Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
01:56am, Thursday, 09'th Apr 2026
Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)
01:26pm, Wednesday, 08'th Apr 2026
Mesoblast (MESO) is upgraded to a speculative Buy as Ryoncil outperforms in pediatric SR-aGVHD and advances rapidly into a registrational DMD trial. Ryoncil's DMD opportunity is underappreciated, with
